Salmeterol xinafoate is a long-acting ?2-adrenergic receptor agonist (LABA) API. It acts as a bronchodilator by selectively relaxing airway smooth muscle. Its key pharmacological feature is its prolonged duration of action, exceeding 12 hours, due to its highly lipophilic side chain anchoring it near the receptor site. This makes it a cornerstone for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It is not indicated for acute relief. The xinafoate salt (1-hydroxy-2-naphthoic acid) enhances its solubility and crystallinity for pharmaceutical formulation. It is almost always formulated in combination with an inhaled corticosteroid for asthma management to mitigate inflammation and improve safety.